We are live on ! Find out more
BLSM

BlossomHill Therapeutics

13.58 USD
-0.44
3.14%
At close Updated Nov 16, 11:35 AM EST
1 day
-3.14%
5 days
-4.3%
1 month
-2.58%
3 months
-17.09%
6 months
-15.13%
Year to date
-15.13%
1 year
-15.13%
5 years
-15.13%
10 years
-15.13%
 

About: BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Employees: 69

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 7.7%
Neutral 92.3%
Negative 0%
Neutral
GlobeNewsWire
3 days ago
BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Alignment with the US Food and Drug Administration (FDA) on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 based on favorable PK, safety, and efficacy data to date Announced SOLARA-2, the single-arm pivotal Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027 Collaboration with Foundation Medicine to develop a companion diagnostic assay for the EGFR C797S resistance mutation $224.9 million in cash and cash equivalents as of September 30, 2026 SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the third quarter 2026 and highlighted recent progress. “We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial.
BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Neutral
GlobeNewsWire
7 days ago
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
Alignment with the US Food and Drug Administration on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 SOLARA-2, the Phase 2 portion of the SOLARA trial, designed with registrational intent to evaluate BH-30643 in patients with EGFR C797S-positive NSCLC; expect to dose first patient in Q1 2027 SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced the outcome of its End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding BH-30643 for the treatment of patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC). BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR™ inhibitor designed to overcome the limitations of currently approved EGFR inhibitors for the treatment of EGFR-mutant NSCLC.
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
Neutral
GlobeNewsWire
12 days ago
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced an upcoming poster presentation highlighting preclinical and clinical data for BH-30236 at the 68th American Society of Hematology (ASH) Annual Meeting, being held December 12-15, 2026, in New Orleans, Louisiana. BH-30236 is a novel, orally bioavailable, macrocyclic CDC-like kinase (CLK) inhibitor that modulates aberrant alternative pre-mRNA splicing, a defining feature implicated in cancer progression and therapeutic resistance across both hematologic malignancies and solid tumors.
BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting
Neutral
GlobeNewsWire
13 days ago
BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced its participation in Guggenheim's 3rd Annual Healthcare Innovations Conference being held at the Intercontinental Boston. Management will participate in a fireside chat on Tuesday, November 10, 2026, at 3:00 pm Eastern Time and will also participate in one-on-one investor meetings.
BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference
Positive
Seeking Alpha
19 days ago
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
BlossomHill Therapeutics achieved major de-risking milestones within 80 days post-IPO, including Fast Track and a key companion diagnostic partnership. I see the C797S lung cancer indication as a strategic beachhead, not a niche, leveraging a clear biomarker and no approved oral targeted therapies. BLSM's $220M pro forma cash supports seven to eight quarters of runway, funding Phase 2 initiation but likely requiring further equity for commercialization.
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
Neutral
GlobeNewsWire
25 days ago
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced a collaboration with Foundation Medicine, Inc. to develop a companion diagnostic assay (CDx) for the EGFR C797S resistance mutation. The collaboration will leverage the ongoing Phase 1/2 SOLARA clinical trial evaluating BH-30643 in the targeted treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients to validate the assay.
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
Neutral
GlobeNewsWire
1 month ago
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 2027
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Neutral
GlobeNewsWire
1 month ago
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering Announced FDA Fast Track designation for BH-30643 for the treatment of advanced EGFR C797S-positive NSCLC SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the second quarter 2026 and highlighted recent progress.
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Neutral
GlobeNewsWire
2 months ago
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no approved targeted therapies BH-30643 demonstrated a favorable safety profile with low rates of dose reduction or discontinuation due to treatment-related adverse events Presentation follows receipt of FDA Fast Track designation for BH-30643 for the treatment of advanced or metastatic EGFR C797S-positive NSCLC SAN DIEGO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S.
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
Neutral
Seeking Alpha
2 months ago
Primary Markets Group August IPO Update
August's seven U.S. IPOs matched the prior month's deal count, while aggregate proceeds declined modestly. The month saw $1.8 billion in total proceeds compared to the $3.0 billion raised in July and the $2.9 billion raised across seven IPOs in August 2025. Issuance was dominated by the healthcare sector, which priced five deals and accounted for over $1.4 billion of the total proceeds raised.
Primary Markets Group August IPO Update
Price charts implemented using Lightweight Charts™